Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Bayer Aktiengesellschaft American Depositary Shares (OP: BAYRY)
108.13 USD  -0.59 (-0.54%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 17, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Bayer Aktiengesellschaft American Depositary Shares
 
< Previous 1 2 3 4 5 Next >
Glaxo Strengthens Indian Presence – Analyst Blog
February 07, 2013
GlaxoSmithKline (GSK) recently increased its holding in its consumer healthcare subsidiary in India, GlaxoSmithKline Consumer Healthcare Ltd, from 43.2% to up to 72.5%. The transaction is valued at... Read More
category Zacks , Syndicated Content
from Money Morning
(JNJ) Back to Neutral on Bayer
December 31, 2012
We are reverting to a Neutral recommendation on Bayer (BAYRY) as we believe that all the positive... Visit StockBlogHub to view complete post. Read More
category Regeneron Pharmaceuticals Inc , REGN , Onyx Pharmaceuticals Inc , and 7 more.
from Stock Blog Hub
German GDP Outlook Cut
December 07, 2012
category Market/Outlook , Europe/2012/Q4 , Europe , and 3 more.
from Wall Street Greek
Bayer AG – ADR (BAYRY) – Bull of the Day
November 05, 2012
Bayer AG's (BAYRY) earnings per share during the third quarter of 2012 came in at EUR1.68 (approx $1.50) compared to EUR1.12 (approx. $1.58) in the year-ago period. The company recorded an 11.5% (5.5%... Read More
category Zacks , Syndicated Content
from Money Morning
(PFS) Bayer’s Stivarga Gains Approval
October 09, 2012
The HealthCare unit of Bayer (BAYRY) recently announced that the US Food and Drug Administration... Visit StockBlogHub to view complete post. Read More
category Onyx Pharmaceuticals Inc , Sanofi/Aventis , Novartis AG , and 9 more.
from Stock Blog Hub
Bayer Upped to Outperform – Analyst Blog
September 19, 2012
Encouraged by strong second quarter 2012 results, an upbeat guidance and a series of positive subsequent developments, we are upgrading Bayer Corporation (BAYRY) to Outperform from Neutral. Our... Read More
category Zacks , Syndicated Content
from Money Morning
How Aveo's Tivo cancer drug stacks up against rivals
August 15, 2012
Across the board the relative safety profile of Tivo stands out. Covestor Ltd. is a registered investment advisor. Covestor licenses investment strategies from its Model Managers to establish... Read More
category Chris Rees , ONXX , Positions , and 5 more.
from Smarter Investing
Greece vs. Germany - A Game for Pride
June 22, 2012
category Europe , Greece/2012/Q2 , Editors/Picks/2012/06 , and 5 more.
from Wall Street Greek
Pipeline Setback For Bayer/JNJ
May 25, 2012
The HealthCare unit of Bayer (BAYRY) and its partner,  Johnson & Johnson’s (NYSE:JNJ) Janssen Research and Development unit, received some disappointing news recently when an advisory panel of the U.S.... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Onyx/Bayer’s Nexavar Disappoints
May 23, 2012
Bayer AG (BAYRY) recently announced that a phase III trial of Nexavar (sorafenib), co-developed and marketed with Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), failed to meet the primary endpoint. The... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Eylea Drives Regeneron To Profit
April 27, 2012
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) first quarter 2012 earnings (excluding special items but including stock-based compensation) of 15 cents per share compared favorably with the Zacks... Read More
category REGN , SNY , Stocks , and 3 more.
from DailyMarkets.com
Eylea Drives Regeneron To Profit
April 27, 2012
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) first quarter 2012 earnings (excluding special items but including stock-based compensation) of 15 cents per share compared favorably with the Zacks... Read More
category REGN , SNY , Stocks , and 3 more.
from DailyMarkets.com
Bayer Seeks Label Expansion
April 16, 2012
The HealthCare unit of Bayer (BAYRY) recently filed an application with the European Medicines Agency (EMA) seeking marketing approval for its blood thinner, Xarelto, for an additional indication in... Read More
category SNY , jnj , Stocks , and 3 more.
from DailyMarkets.com
Biogen’s Fampyra Launched In Canada
April 13, 2012
Biogen Idec (NASDAQ:BIIB) recently announced the launch of Fampyra in Canada. Fampyra gained approval in Canada in February 2012 for the symptomatic improvement of walking ability in adult multiple... Read More
category TEVA , External Research , Contributor , and 8 more.
from DailyMarkets.com
Label Updation By Bayer
April 12, 2012
The HealthCare unit of Bayer (BAYRY) has updated the labels in the US for the oral contraceptives in its portfolio which contain drospirenone following a directive from the US Food and Drug... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Positive Data On Bayer/Onyx Candidate
April 10, 2012
The HealthCare unit at Bayer (BAYRY) and partner Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) recently announced that their candidate regorafenib (BAY 73-4506) fared well in a phase III study (GRID:... Read More
category NVS , ONXX , Stocks , and 4 more.
from DailyMarkets.com
Still Neutral On Ardea Biosciences
April 04, 2012
We are maintaining our Neutral recommendation on Ardea Biosciences Inc. (NASDAQ:RDEA) with a target price of $23.00. Ardea Biosciences, headquartered in San Diego, California, focuses on the discovery... Read More
category SVNT , REGN , RDEA , and 4 more.
from DailyMarkets.com
Bayer Walks A Neutral Path
April 04, 2012
We are maintaining our Neutral recommendation on Germany’s Bayer (BAYRY) with a target price of $76.00. Headquartered in Leverkusen, Germany, Bayer is one of the world’s largest healthcare and chemical... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Management Change At Endo Pharma
March 30, 2012
Endo Pharmaceuticals Holdings Inc. (NASDAQ:ENDP) recently announced a change in its management team. The company announced that Mr. Tony Bihl, the man at the helm of Endo devices operating company (a... Read More
category ENDP , BDSI , Stocks , and 3 more.
from DailyMarkets.com
Pipeline Progress At Regeneron
March 29, 2012
Recently, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and partner Sanofi (NYSE:SNY) announced encouraging data from two mid-stage studies which evaluated their candidate SAR236553/REGN727 for reducing... Read More
category REGN , SNY , Stocks , and 4 more.
from DailyMarkets.com
Neutral Stance For Onyx Pharma
March 23, 2012
We continue to have a Neutral recommendation on Onyx Pharmaceuticals Inc. (NASDAQ:ONXX), which posted earnings of $1.44 per share in the fourth quarter 2011, in contrast to the Zacks Consensus Estimate... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Australian Clearance For Eye-Drug Eylea
March 09, 2012
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and the HealthCare unit of Bayer (BAYRY) announced recently that their eye-drug Eylea has been cleared by the Australian Therapeutic Goods Administration... Read More
category NVS , REGN , Stocks , and 3 more.
from DailyMarkets.com
Sigma Aldrich Invests In India
March 08, 2012
As per industry reports, Sigma Aldrich Corporation (NASDAQ:SIAL), a global lab chemical and life science company, announced its intention to open a distribution center and packaging facility in... Read More
category SIAL , Stocks , External Research , and 2 more.
from DailyMarkets.com
Revenues Rise At Bayer
March 01, 2012
Bayer’s (BAYRY) earnings per share during the fourth quarter of 2011 came in at €0.97 (approx $1.31) compared to €0.95 (approx. $1.29) in the year-ago period. Higher revenues boosted earnings. The... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
Onyx Beats; Says 2012 Vital
February 24, 2012
Onyx Pharmaceuticals Inc. (NASDAQ:ONXX) reported fourth quarter 2011 earnings of $1.44 per share, in contrast to the Zacks Consensus Estimate of a loss of 56 cents and the year-ago loss of 37 cents per... Read More
category ONXX , Stocks , External Research , and 2 more.
from DailyMarkets.com
Regeneron Treads The Neutral Path
February 22, 2012
We continue to have a Neutral recommendation on Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) following the appraisal of fourth quarter and full-year 2011 results. Regeneron suffered a wider... Read More
category NVS , REGN , JPM , and 4 more.
from DailyMarkets.com
Regeneron’s Loss Widens, Eylea Grows
February 15, 2012
Regeneron Pharmaceuticals Inc.’s (NASDAQ:REGN) fourth quarter 2011 net loss (excluding special items but including stock-based compensation) of 54 cents per share was narrower than the Zacks Consensus... Read More
category REGN , SNY , JPM , and 4 more.
from DailyMarkets.com
Watson Files ANDA For Beyaz Generic
February 13, 2012
Watson Pharmaceuticals Inc. (NYSE:WPI) recently confirmed that it has filed an abbreviated new drug application (ANDA) with the US Food and Drug Administration (FDA) to market the generic version of... Read More
category jnj , WPI , Stocks , and 3 more.
from DailyMarkets.com
Sigma Beats On Revenues
February 09, 2012
Sigma-Aldrich Corporation (NASDAQ:SIAL) reported fourth quarter 2011 earnings of 91 cents per share, surpassing the Zacks Consensus Estimate of 89 cents. Results also came in better than the earnings... Read More
category SIAL , Stocks , External Research , and 2 more.
from DailyMarkets.com
Good News For Bayer/JNJ
January 24, 2012
Encouraging news flowed in at Bayer (BAYRY) from Japan when the regulatory authorities of the country cleared the company’s potential blockbuster blood thinner Xarelto for stroke prevention in patients... Read More
category jnj , Stocks , External Research , and 2 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here